TipRanks
Advertisement
Advertisement
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
PremiumCompany AnnouncementsSarepta Resolves AAVrh74 Gene Therapy Patent Dispute
9d ago
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
Premium
The Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
22d ago
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Premium
Ratings
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
24d ago
Unusually active option classes on open August 7th
PremiumThe FlyUnusually active option classes on open August 7th
2M ago
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
Premium
Company Announcements
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
2M ago
Sarepta price target lowered to $35 from $37 at Oppenheimer
Premium
The Fly
Sarepta price target lowered to $35 from $37 at Oppenheimer
2M ago
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
PremiumThe FlyMorgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
2M ago
Sarepta Therapeutics Appoints Michael Severino as CEO
Premium
Company Announcements
Sarepta Therapeutics Appoints Michael Severino as CEO
2M ago
Sarepta appoints Severino as Chief Executive Officer
Premium
The Fly
Sarepta appoints Severino as Chief Executive Officer
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―